{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:23:19Z","timestamp":1792610599158,"version":"4.5.0"},"reference-count":93,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.csbj.2015.01.003","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T23:05:44Z","timestamp":1423609544000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients"],"prefix":"10.34133","volume":"13","author":[{"given":"Katharina","family":"G\u00f6hring","sequence":"first","affiliation":[{"name":"Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Hamprecht","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Jahn","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"e_1_3_1_2_1_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention","volume":"13","author":"Kotton C.N.","year":"2013","unstructured":"Kotton C.N.: CMV: prevention. Diagn Ther Am J Transplant 2013; 13: 24.","journal-title":"Diagn Ther Am J Transplant"},{"key":"e_1_3_1_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.873-883.2005"},{"key":"e_1_3_1_2_3_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.humimm.2004.02.007","article-title":"Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs","volume":"65","author":"Baldanti F.","year":"2004","unstructured":"Baldanti F., Lurain N. and Gerna G.: Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004; 65: 403.","journal-title":"Hum Immunol"},{"key":"e_1_3_1_2_4_2","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood.V96.9.3286","article-title":"Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes","volume":"96","author":"Eckle T.","year":"2000","unstructured":"Eckle T., Prix L., Jahn G., Klingebiel T., Hangretinger R., Selle B. et al: Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96: 3286.","journal-title":"Blood"},{"key":"e_1_3_1_2_5_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/srin.2002.36447","article-title":"Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients","volume":"17","author":"Limaye A.P.","year":"2002","unstructured":"Limaye A.P.: Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17: 265.","journal-title":"Semin Respir Infect"},{"key":"e_1_3_1_2_6_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotype","volume":"85","author":"Chevilotte M.","year":"2010","unstructured":"Chevilotte M., von Einem J., Meier B.M., Lin F.M., Kestler H.A. and Mertens T.: A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotype. Antiviral Res 2010; 85: 318.","journal-title":"Antiviral Res"},{"key":"e_1_3_1_2_7_2","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle D.C.","year":"2010","unstructured":"Quenelle D.C., Lampert B., Collins D.J., Rice T.L., Painter G.R. and Kern E.R.: Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010; 202: 1492.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.10.011"},{"key":"e_1_3_1_2_9_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben S.","year":"2014","unstructured":"Stoelben S., Arns W., Renders L., Hummel J., M\u00fchlfeld A., Stangl M. et al: Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014; 27: 77.","journal-title":"Transpl Int"},{"key":"e_1_3_1_2_10_2","volume-title":"Oral maribavir for treatment of resistant or refractory cytomegalovirus infections in transplant recipients49th intersci. conf. Antimicrobiol agents chemother San Francisco,CA","author":"Avery R.K.","year":"2009","unstructured":"Avery R.K., Marty F.M., Strasfeld S., Lee I., Arrieta A., Chou S. et al: Oral maribavir for treatment of resistant or refractory cytomegalovirus infections in transplant recipients. Abstr V-1256. Abstr 49th intersci. conf. Antimicrobiol agents chemother San Francisco,CA. : 2009."},{"key":"e_1_3_1_2_11_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double blind, placebo controlled, randomised trial","volume":"11","author":"Marty F.M.","year":"2011","unstructured":"Marty F.M., Ljungman P., Papanicolaou G.A., Winston D.J., Chemaly R.F., Strasfeld L. et al: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double blind, placebo controlled, randomised trial. Lancet Infect Dis 2011; 11: 284.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_1_2_12_2","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dose 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston D.J.","year":"2012","unstructured":"Winston D.J., Saliba F., Blumberg E., Abouljoud M., Gracia-Diaz J.B., Gross J.A. et al: Efficacy and safety of maribavir dose 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12: 3021.","journal-title":"Am J Transplant"},{"key":"e_1_3_1_2_13_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain N.S.","year":"2010","unstructured":"Lurain N.S. and Chou S.: Antiviral drug resistance of human cytomegalovirus. J Clin Microbiol Rev 2010; 23: 689.","journal-title":"J Clin Microbiol Rev"},{"key":"e_1_3_1_2_14_2","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1128\/JVI.00384-14","article-title":"Innate nuclear sensor IFI16 translocates into the cytoplasm during early stage on in vitro human cytomegalovirus infection and is entrapped in the egressing virions during late stage","volume":"88","author":"Dell\u00b4Oste V.","year":"2014","unstructured":"Dell\u00b4Oste V., Gatti D., Gugliesi F., De Andrea M., Bawadekar M., Lo Cigno I. et al: Innate nuclear sensor IFI16 translocates into the cytoplasm during early stage on in vitro human cytomegalovirus infection and is entrapped in the egressing virions during late stage. J Virol 2014; 88: 6970.","journal-title":"J Virol"},{"key":"e_1_3_1_2_15_2","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How I treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh M.","year":"2009","unstructured":"Boeckh M. and Ljungman P.: How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711.","journal-title":"Blood"},{"key":"e_1_3_1_2_16_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton C.N.","year":"2010","unstructured":"Kotton C.N., Kumar D. and Caliendo A.M.: International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.","journal-title":"Transplantation"},{"key":"e_1_3_1_2_17_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre H.A.","year":"2011","unstructured":"Myhre H.A., Haug Dorenberg D., Kristiansen K.I., Rollag H., Leivestad T., Asber A. et al: Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011; 92: 217.","journal-title":"Transplantation"},{"key":"e_1_3_1_2_18_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802678138"},{"key":"e_1_3_1_2_19_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e32834cfb58","article-title":"The biology og cytomegalovirus drug resistance","volume":"24","author":"Hakki M.","year":"2011","unstructured":"Hakki M. and Chou S.: The biology og cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24: 605.","journal-title":"Curr Opin Infect Dis"},{"key":"e_1_3_1_2_20_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka P.","year":"2008","unstructured":"Lischka P. and Zimmermann H.: Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008; 8: 541.","journal-title":"Curr Opin Pharmacol"},{"key":"e_1_3_1_2_21_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei G.","year":"2009","unstructured":"Andrei G., De C.E. and Snoeck R.: Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 2009; 9: 162.","journal-title":"Infect Disord Drug Targets"},{"key":"e_1_3_1_2_22_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"48","author":"Eid A.J.","year":"2008","unstructured":"Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P. and Razonable R.R.: Emergence of drug resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 48: 162.","journal-title":"Clin Transplant"},{"key":"e_1_3_1_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.7.2291-2296.1999"},{"key":"e_1_3_1_2_24_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI-)-treated patients and NRTI-na\u00efve patients","volume":"199","author":"Margeridon-Thermet S.","year":"2009","unstructured":"Margeridon-Thermet S., Shulman N.S., Ahmed A., Shahari R., Liu T., Wang C. et al: Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI-)-treated patients and NRTI-na\u00efve patients. J Infect Dis 2009; 199: 1275.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_25_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.6468307"},{"key":"e_1_3_1_2_26_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2353\/jmoldx.2009.080153","article-title":"Dynamics of the emergence of a drug resistant human cytomegalovirus strain in a pediatric stem cell transplant recipient detected by a new real-time PCR approach","volume":"11","author":"G\u00f6hring K.","year":"2009","unstructured":"G\u00f6hring K., Feuchtinger T., Mikeler E., Lang P., Jahn G., Handgretinger R. et al: Dynamics of the emergence of a drug resistant human cytomegalovirus strain in a pediatric stem cell transplant recipient detected by a new real-time PCR approach. J Mol Diagn 2009; 11: 364.","journal-title":"J Mol Diagn"},{"key":"e_1_3_1_2_27_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/173.3.523","article-title":"Detection of ganciclovir resistance mutations of cytomegalovirus (CMV) DNA in leucozytes of patients with fatal disseminated CMV diseases","volume":"173","author":"Boivin G.","year":"1996","unstructured":"Boivin G., Chou S., Quirk M.R., Erice A. and Jordan M.C.: Detection of ganciclovir resistance mutations of cytomegalovirus (CMV) DNA in leucozytes of patients with fatal disseminated CMV diseases. J Infect Dis 1996; 173: 523.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_28_2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/324672","article-title":"Rate of emergence of cytomegalovirus (CMV) mutations in leucocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis","volume":"184","author":"Boivin G.","year":"2001","unstructured":"Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R. and Roberts N.A.: Rate of emergence of cytomegalovirus (CMV) mutations in leucocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184: 1598.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_29_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/171.3.576","article-title":"Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance","volume":"171","author":"Chou S.","year":"1995","unstructured":"Chou S., Erice A., Jordan M.C., Vercellotti G.M., Michels K.R., Talarico C.L. et al: Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171: 576.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_30_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/infdis\/172.1.239","article-title":"Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates","volume":"172","author":"Chou S.","year":"1995","unstructured":"Chou S., Guentzel S., Michels K.R., Miner R.C. and Drew W.L.: Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_31_2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/516446","article-title":"Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients","volume":"175","author":"Erice A.","year":"1997","unstructured":"Erice A., Gil-Roda J.L., Perez L., Balfour H.H., Sannerud K.J., Hanson M.N. et al: Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175: 1087.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_32_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00002030-199802000-00001","article-title":"Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients","volume":"12","author":"Gilbert C.","year":"1998","unstructured":"Gilbert C., Handfiels J., Toma E., Lalonde R., Bergeron M.G. and Boivin G.: Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 1998; 12: 125.","journal-title":"AIDS"},{"key":"e_1_3_1_2_33_2","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1128\/JCM.01141-06","article-title":"Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance","volume":"44","author":"G\u00f6hring K.","year":"2006","unstructured":"G\u00f6hring K., Mikeler E., Jahn G. and Hamprecht K.: Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance. J Clin Microbiol 2006; 44: 4541.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_1_2_34_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/135965350801300308","article-title":"Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance","volume":"13","author":"G\u00f6hring K.","year":"2008","unstructured":"G\u00f6hring K., Mikeler E., Jahn G., Rohde F. and Hamprecht K.: Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. Antivir Ther 2008; 13: 461.","journal-title":"Antivir Ther"},{"key":"e_1_3_1_2_35_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1399-3062.1999.010204.x","article-title":"Antiviral drug resistance in human cytomegalovirus","volume":"1","author":"Chou S.","year":"1999","unstructured":"Chou S.: Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999; 1: 105.","journal-title":"Transpl Infect Dis"},{"key":"e_1_3_1_2_36_2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.44.3.688-692.2000","article-title":"A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates","volume":"44","author":"Landry M.L.","year":"2000","unstructured":"Landry M.L., Stanat S., Biron K., Brambilla P., Britt W., Jokela J. et al: A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000; 44: 688.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_37_2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral-drug-resistant cytomegalovirus isolates from solid organ transplant recipients","volume":"186","author":"Lurain N.S.","year":"2002","unstructured":"Lurain N.S., Bhorade S.M., Pursell K.J., Avery R.K., Yeldandi V.V., Isada C.M. et al: Analysis and characterization of antiviral-drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_38_2","first-page":"29","article-title":"A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains","volume":"24","author":"Prix L.","year":"1998","unstructured":"Prix L., Maierl J., Jahn G. and Hamprecht K.: A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J Clin Virol 1998; 24: 29.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_39_2","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/AAC.00165-09","article-title":"Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness","volume":"53","author":"Chevillotte M.","year":"2009","unstructured":"Chevillotte M., Schubert A., Mertens T. and von Einem J.: Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob Agents Chemother 2009; 53: 3752.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/358162a0"},{"key":"e_1_3_1_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.7.5927-5936.1998"},{"key":"e_1_3_1_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gni035"},{"key":"e_1_3_1_2_43_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/505882","article-title":"Characterization of human citomegalovirus (HCMV) UL97 mutations found in a valganciclovir\/oral ganciclovir prophylactic trial by use of bacterial artificial chromosom containing the HCMV genome","volume":"194","author":"Martin M.","year":"2006","unstructured":"Martin M., Gilbert E., Covington E. and Boivin G.: Characterization of human citomegalovirus (HCMV) UL97 mutations found in a valganciclovir\/oral ganciclovir prophylactic trial by use of bacterial artificial chromosom containing the HCMV genome. J Infect Dis 2006; 194: 579.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.10.8320-8329.1999"},{"key":"e_1_3_1_2_45_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2144\/000112096","article-title":"Two-step mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli","volume":"40","author":"Tischer B.K.","year":"2006","unstructured":"Tischer B.K., von Einem J., Kaufer B. and Osterrieder N.: Two-step mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 2006; 40: 191.","journal-title":"Biotechniques"},{"key":"e_1_3_1_2_46_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-60761-652-8_30","article-title":"En passant mutagenesis: a two step markerless recombination system","volume":"634","author":"Tischer B.K.","year":"2010","unstructured":"Tischer B.K., Smith G.A. and Osterrieder N.: En passant mutagenesis: a two step markerless recombination system. Methods Mol Biol 2010; 634: 421.","journal-title":"Methods Mol Biol"},{"key":"e_1_3_1_2_47_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/AAC.47.1.442-443.2003","article-title":"High impact of an expanded restriction fragment length polymorphism assay on detection of gancoclovir- resistant UL97 mutants of human cytomegalovirus","volume":"47","author":"Eckle T.","year":"2003","unstructured":"Eckle T., Jahn G. and Hamprecht K.: High impact of an expanded restriction fragment length polymorphism assay on detection of gancoclovir- resistant UL97 mutants of human cytomegalovirus. Antimicrob Agents Chemother 2003; 47: 242.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_48_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2013.01.003","article-title":"Dynamics of coexisting HCMV UL97- and UL54 drug resistance assicoated mutations in patients after haematopoetic cell transplantation","volume":"57","author":"G\u00f6hring K.","year":"2013","unstructured":"G\u00f6hring K., Wolf D., Bethge W., Mikeler Faul C., Vogel W. et al: Dynamics of coexisting HCMV UL97- and UL54 drug resistance assicoated mutations in patients after haematopoetic cell transplantation. J Clin Virol 2013; 57: 43.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_49_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcv.2007.07.003","article-title":"Emergence and persistence of multiple antiviral-resistant CMV strains in a highly imunocompromised child","volume":"40","author":"Iwanesko J.M.","year":"2007","unstructured":"Iwanesko J.M., Scott G.M., Ziegler J.B. and Rawlinson W.D.: Emergence and persistence of multiple antiviral-resistant CMV strains in a highly imunocompromised child. J Clin Virol 2007; 40: 152.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_50_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83286-0"},{"key":"e_1_3_1_2_51_2","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou S.","year":"2010","unstructured":"Chou S.: Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54: 2372.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_52_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1386-6532(99)00031-1","article-title":"Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir","volume":"13","author":"Abraham B.","year":"1999","unstructured":"Abraham B., Lastere S., Reynes J., Bibollet-Ruche F., Vidal N. and Segondy M.: Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir. J Clin Virol 1999; 13: 141.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_53_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2008.11.003","article-title":"Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection","volume":"81","author":"Boutolleau D.","year":"2009","unstructured":"Boutolleau D., Deback C., Bressollette-Bodin C., Varnous S., Dhedin N., Barrou B. et al: Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81: 174.","journal-title":"Antiviral Res"},{"key":"e_1_3_1_2_54_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/338362","article-title":"Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir","volume":"185","author":"Chou S.","year":"2002","unstructured":"Chou S., Waldemer R.H., Senters A.E., Michels S., Kemble G.W., Miner R.C. et al: Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185: 162.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_55_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/514041","article-title":"High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes","volume":"176","author":"Smith I.L.","year":"1997","unstructured":"Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R. and Spector S.A.: High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176: 69.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_56_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1172\/JCI117648","article-title":"Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma","volume":"95","author":"Wolf D.G.","year":"1995","unstructured":"Wolf D.G., Smith I.L., Lee D.J., Freeman W.R., Flores-Aguilar M. and Spector S.A.: Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995; 95: 257.","journal-title":"J Clin Invest"},{"key":"e_1_3_1_2_57_2","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou S.","year":"2005","unstructured":"Chou S., Van Wechel L.C., Lichy H.M. and Marousek G.I.: Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49: 2710.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_58_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0002-9394(01)01161-8","article-title":"Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. The Cytomegalovirus and Viral Resistance Study Group Report Number 8","volume":"132","author":"Jabs D.A.","year":"2001","unstructured":"Jabs D.A., Martin B.K., Forman M.S., Dunn J.P., Davis J.L., Weinberg D.V. et al: Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol 2001; 132: 700.","journal-title":"Am J Ophthalmol"},{"key":"e_1_3_1_2_59_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye A.P.","year":"2000","unstructured":"Limaye A.P., Corey L., Koelle D.M., Davis C.L. and Boeckh M.: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.","journal-title":"Lancet"},{"key":"e_1_3_1_2_60_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2006.11.005","article-title":"Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients","volume":"38","author":"Marfori J.E.","year":"2007","unstructured":"Marfori J.E., Exner M.M., Marousek G.I., Chou S. and Drew W.L.: Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007; 38: 120.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_61_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2010.01.009","article-title":"Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis","volume":"47","author":"Martin M.","year":"2010","unstructured":"Martin M., Goyette N., Ives J. and Boivin G.: Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010; 47: 321.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1204"},{"key":"e_1_3_1_2_63_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye A.P.","year":"2002","unstructured":"Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L. et al: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_64_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(01)00202-9","article-title":"GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97is partially reconstituted by a second mutation at D605E","volume":"53","author":"Ijichi O.","year":"2002","unstructured":"Ijichi O., Michel D., Mertens T., Miyata K. and Eizuru Y.: GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97is partially reconstituted by a second mutation at D605E. Antiviral Res 2002; 53: 135.","journal-title":"Antiviral Res"},{"key":"e_1_3_1_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(97)00093-1"},{"key":"e_1_3_1_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.2.796-800.1995"},{"key":"e_1_3_1_2_67_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.44.1.183-185.2000","article-title":"A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir","volume":"44","author":"Chou S.","year":"2000","unstructured":"Chou S. and Meichsner L.C.: A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob Agents Chemother 2000; 44: 183.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_68_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0166-3542(01)00211-X","article-title":"Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system","volume":"54","author":"Baldanti F.","year":"2002","unstructured":"Baldanti F., Michel D., Simoncini L., Heuschmid M., Zimmermann A., Minisini R. et al: Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res 2002; 54: 59.","journal-title":"Antiviral Res"},{"key":"e_1_3_1_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(98)00051-5"},{"key":"e_1_3_1_2_70_2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.49.4.1580-1583.2005","article-title":"Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient","volume":"49","author":"Hantz S.","year":"2005","unstructured":"Hantz S., Michel D., Fillet A.M., Guigonis V., Champier G., Mazeron M.C. et al: Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother 2005; 49: 1580.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_71_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.42.2.444","article-title":"The Cys607Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients","volume":"42","author":"Baldanti F.","year":"1998","unstructured":"Baldanti F., Underwood M.R., Talarico C.L., Simoncini L., Sarasini A., Biron K.K. et al: The Cys607Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 1998; 42: 444.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_72_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.antiviral.2013.09.026","article-title":"Generation and characterisation of defined HCMV UL97- and UL54-mutants conferring drug resistance","volume":"100","author":"Fischer L.","year":"2013","unstructured":"Fischer L., Laib-Sampaio K., Jahn G., Hamprecht K. and G\u00f6hring K.: Generation and characterisation of defined HCMV UL97- and UL54-mutants conferring drug resistance. Antiviral Res 2013; 100: 575.","journal-title":"Antiviral Res"},{"key":"e_1_3_1_2_73_2","article-title":"Identification of newly detected, drug-related HCMV UL97- and UL54- mutations using a modified plaque reduction assay","author":"Fischer L.","year":"2015","unstructured":"Fischer L., Laib-Sampaio K., Jahn G., Hamprecht K. and G\u00f6hring K.: Identification of newly detected, drug-related HCMV UL97- and UL54- mutations using a modified plaque reduction assay. J Clin Virol 2015; . [submitted for publication].","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_74_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou S.","year":"2003","unstructured":"Chou S., Lurain N.S., Thompson K.D., Miner R.C. and Drew W.L.: Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 32.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_75_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/AAC.00633-06","article-title":"Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates","volume":"51","author":"Scott G.M.","year":"2007","unstructured":"Scott G.M., Weinberg A., Rawlinson W.D. and Chou S.: Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51: 89.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_76_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1086\/517302","article-title":"Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease","volume":"176","author":"Chou S.","year":"1997","unstructured":"Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P. et al: Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176: 786.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_77_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/135965350601100416","article-title":"A novel mutation in theUL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","volume":"11","author":"Ducancelle A.","year":"2006","unstructured":"Ducancelle A., Champier G., Alain S., Petit F., Le Pors M.J. and Mazeron M.C.: A novel mutation in theUL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir Ther 2006; 11: 537.","journal-title":"Antivir Ther"},{"key":"e_1_3_1_2_78_2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1998.9299","article-title":"A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture","volume":"248","author":"Cihlar T.","year":"1998","unstructured":"Cihlar T., Fuller M.D., Mulato A.S. and Cherrington J.M.: A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998; 248: 382.","journal-title":"Virology"},{"key":"e_1_3_1_2_79_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2008.04.005","article-title":"Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","volume":"43","author":"Chou S.","year":"2008","unstructured":"Chou S., Marousek G., Li S. and Weinberg A.: Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol 2008; 43: 107.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_80_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(01)00160-3","article-title":"Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity","volume":"23","author":"Mousavi-Jazi M.","year":"2001","unstructured":"Mousavi-Jazi M., Schloss L., Drew W.L., Linde A., Miner R.C., Harmenberg J. et al: Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001; 23: 1.","journal-title":"J Clin Virol"},{"key":"e_1_3_1_2_81_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/JCM.43.1.208-213.2005","article-title":"How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients","volume":"43","author":"Springer K.L.","year":"2005","unstructured":"Springer K.L., Chou S., Li S., Giller R.H., Quinones R., Shira J.E. et al: How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43: 208.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_1_2_82_2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/jvi.70.3.1390-1395.1996","article-title":"Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS","volume":"70","author":"Baldanti F.","year":"1996","unstructured":"Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarazini A. et al: Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996; 70: 1390.","journal-title":"J Virol"},{"key":"e_1_3_1_2_83_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/368385","article-title":"Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"187","author":"Weinberg A.","year":"2003","unstructured":"Weinberg A., Jabs D.A., Chou S., Martin B.K., Lurain N.S., Forman M.S. et al: Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003; 187: 777.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_84_2","doi-asserted-by":"publisher","DOI":"10.1086\/587106"},{"key":"e_1_3_1_2_85_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1086\/515648","article-title":"Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy","volume":"178","author":"Chou S.","year":"1998","unstructured":"Chou S., Marousek G., Parenti D.M., Gordon S.M., LaVoy A.G., Ross J.G. et al: Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998; 178: 526.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_86_2","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou S.","year":"2007","unstructured":"Chou S., Marousek G.I., Van Wechel L.C., Li S. and Weinberg A.: Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51: 4160.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_87_2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1086\/317618","article-title":"A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance","volume":"182","author":"Chou S.","year":"2000","unstructured":"Chou S., Miner R.C. and Drew W.L.: A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000; 182: 1765.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_88_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/AAC.37.1.19","article-title":"A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives","volume":"37","author":"Sullivan V.","year":"1993","unstructured":"Sullivan V., Biron K.K., Talarico C., Stanat S.C., Davis M., Pozzi L.M. et al: A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993; 37: 19.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_89_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/346240","article-title":"Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain","volume":"187","author":"Hamprecht K.","year":"2003","unstructured":"Hamprecht K., Eckle T., Prix L., Faul C., Einsele H. and Jahn G.: Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003; 187: 139.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_90_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/314877","article-title":"A comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child","volume":"180","author":"Prix L.","year":"1999","unstructured":"Prix L., Hamprecht K., Holzh\u00fcter B., Handgretinger R., Klingebiel T. and Jahn G.: A comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J Infect Dis 1999; 180: 491.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_2_91_2","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1128\/AAC.00259-10","article-title":"Differentiation between polymorphism and resistance-associated mutations in human cytomegalovirus DNA polymerase","volume":"54","author":"Chevilotte M.","year":"2010","unstructured":"Chevilotte M., Ersing I., Mertens T. and von Einem J.: Differentiation between polymorphism and resistance-associated mutations in human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 2010; 54: 5004.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_2_92_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00705-012-1479-4","article-title":"A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients","volume":"158","author":"Zhang Y.","year":"2013","unstructured":"Zhang Y., Zhao Z., Sun J., Cao G., Zhao F., Hu J. et al: A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients. Arch Virol 2013; 158: 247.","journal-title":"Arch Virol"},{"key":"e_1_3_1_2_93_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2013.02.002","article-title":"Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model","volume":"98","author":"Hantz S.","year":"2013","unstructured":"Hantz S., Cotin S., Borst E., Couvreux A., Salmier A., Garrigue I. et al: Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. Antiviral Res 2013; 98: 130.","journal-title":"Antiviral Res"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037015000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037015000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2015.01.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:51:23Z","timestamp":1778014283000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2015.01.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":93,"alternative-id":["10.1016\/j.csbj.2015.01.003"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2015.01.003","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2015.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}